Answer
Diarrhoea is very common during elotuzumab combination treatment in patients with multiple myeloma, occurring in more than 10% of patients; Grade 3/4 diarrhoea is common.
Sources for this answer
- Empliciti 300 mg and 400 mg powder for concentrate for solution for infusionBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.8 Undesirable effects · Version 12Document updated
Sources checked